Comparison of Two Prognostic Models in Patients with Metastatic
Renal Cancer Treated with Sunitinib: a Retrospective,
Registry-Based Study

J 2015

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

KUBACKOVA, Katerina; Bohuslav MELICHAR; Zbyněk BORTLÍČEK; Tomáš PAVLÍK; Alexandr POPRACH et al.

Základní údaje

Originální název

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

Autoři

Vydání

Targeted Oncology, Dordrecht, Springer, 2015, 1776-2596

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.197

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00085865

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1007/s11523-015-0366-9

UT WoS

000365770300010

EID Scopus

2-s2.0-84949100041

Klíčová slova anglicky

CELL CARCINOMA; TARGETED THERAPY; SURVIVAL; VALIDATION; PROGRESSION; CYTOKINES; CRITERIA; DATABASE

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 1. 2016 15:59, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

The study aimed to compare two prognostic models in terms of progression-free survival (PFS), median overall survival (OS), and 1-year survival in patients treated first-line with sunitinib for metastatic renal cell carcinoma (mRCC). Data from patients who met prognostic model criteria for recording of baseline parameters and outcomes in the Czech Patient Registry RENal Information System (RENIS) were included in the retrospective analysis (n = 495). Performance of the modified Memorial Sloan Kettering Cancer Center (MSKCC) model and International Database Consortium (IDC) model was compared. PFS and OS were estimated using the Kaplan-Meier method. The statistical significance of differences in Kaplan-Meier estimates was assessed using the log-rank test. Median OS for prognostic groups according to MSKCC and IDC criteria, respectively, was 39.5 months (95 % confidence interval [CI]: 23.9-55.2) versus 44.3 months (95 % CI: 31.6-56.9) for favourable-risk patients (no adverse factors), 28.5 months (95 % CI: 20.1-36.8) versus 24.8 months (95 % CI: 19.8-29.8) for intermediate-risk patients (1-2 adverse factors), and 10.6 months (95 % CI: 6.3-14.8) versus 9.3 months (95 % CI: 5.1-13.5) for poor-risk patients (a parts per thousand yen3 adverse factors). The majority of MSKCC poor-risk patients (54.1 %, n = 72) were reclassified as intermediate-risk using IDC criteria, and 20.2 % (n = 61) of MSKCC intermediate-risk patients were reclassified to the IDC favourable-risk group. Both prognostic models were validated in the present cohort. Use of the IDC model resulted in an upward shift in prognostic assessment compared to the MSKCC model.

Citovat

KUBACKOVA, Katerina; Bohuslav MELICHAR; Zbyněk BORTLÍČEK; Tomáš PAVLÍK; Alexandr POPRACH; Marek SVOBODA; Radek LAKOMY; Rostislav VYZULA; Igor KISS; Ladislav DUŠEK; Jana PRAUSOVA a Tomas BUCHLER. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study. Targeted Oncology. Dordrecht: Springer, 2015, roč. 10, č. 4, s. 557-563. ISSN 1776-2596. Dostupné z: https://doi.org/10.1007/s11523-015-0366-9.

@article{1323991,
   author = {Kubackova, Katerina and Melichar, Bohuslav and Bortlíček, Zbyněk and Pavlík, Tomáš and Poprach, Alexandr and Svoboda, Marek and Lakomy, Radek and Vyzula, Rostislav and Kiss, Igor and Dušek, Ladislav and Prausova, Jana and Buchler, Tomas},
   article_location = {Dordrecht},
   article_number = {4},
   doi = {https://doi.org/10.1007/s11523-015-0366-9},
   keywords = {CELL CARCINOMA; TARGETED THERAPY; SURVIVAL; VALIDATION; PROGRESSION; CYTOKINES; CRITERIA; DATABASE},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study},
   volume = {10},
   year = {2015}
}

TY  - JOUR
ID  - 1323991
AU  - Kubackova, Katerina - Melichar, Bohuslav - Bortlíček, Zbyněk - Pavlík, Tomáš - Poprach, Alexandr - Svoboda, Marek - Lakomy, Radek - Vyzula, Rostislav - Kiss, Igor - Dušek, Ladislav - Prausova, Jana - Buchler, Tomas
PY  - 2015
TI  - Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study
JF  - Targeted Oncology
VL  - 10
IS  - 4
SP  - 557-563
EP  - 557-563
PB  - Springer
SN  - 17762596
KW  - CELL CARCINOMA
KW  - TARGETED THERAPY
KW  - SURVIVAL
KW  - VALIDATION
KW  - PROGRESSION
KW  - CYTOKINES
KW  - CRITERIA
KW  - DATABASE
N2  - The study aimed to compare two prognostic models in terms of progression-free survival (PFS), median overall survival (OS), and 1-year survival in patients treated first-line with sunitinib for metastatic renal cell carcinoma (mRCC). Data from patients who met prognostic model criteria for recording of baseline parameters and outcomes in the Czech Patient Registry RENal Information System (RENIS) were included in the retrospective analysis (n = 495). Performance of the modified Memorial Sloan Kettering Cancer Center (MSKCC) model and International Database Consortium (IDC) model was compared. PFS and OS were estimated using the Kaplan-Meier method. The statistical significance of differences in Kaplan-Meier estimates was assessed using the log-rank test. Median OS for prognostic groups according to MSKCC and IDC criteria, respectively, was 39.5 months (95 % confidence interval [CI]: 23.9-55.2) versus 44.3 months (95 % CI: 31.6-56.9) for favourable-risk patients (no adverse factors), 28.5 months (95 % CI: 20.1-36.8) versus 24.8 months (95 % CI: 19.8-29.8) for intermediate-risk patients (1-2 adverse factors), and 10.6 months (95 % CI: 6.3-14.8) versus 9.3 months (95 % CI: 5.1-13.5) for poor-risk patients (a parts per thousand yen3 adverse factors). The majority of MSKCC poor-risk patients (54.1 %, n = 72) were reclassified as intermediate-risk using IDC criteria, and 20.2 % (n = 61) of MSKCC intermediate-risk patients were reclassified to the IDC favourable-risk group. Both prognostic models were validated in the present cohort. Use of the IDC model resulted in an upward shift in prognostic assessment compared to the MSKCC model.
ER  -

KUBACKOVA, Katerina; Bohuslav MELICHAR; Zbyněk BORTLÍČEK; Tomáš PAVLÍK; Alexandr POPRACH; Marek SVOBODA; Radek LAKOMY; Rostislav VYZULA; Igor KISS; Ladislav DUŠEK; Jana PRAUSOVA a Tomas BUCHLER. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study. \textit{Targeted Oncology}. Dordrecht: Springer, 2015, roč.~10, č.~4, s.~557-563. ISSN~1776-2596. Dostupné z: https://doi.org/10.1007/s11523-015-0366-9.

Přehled o publikaci